An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Degarelix (Primary) ; Goserelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PANDA
- Sponsors Ferring Pharmaceuticals
- 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Jan 2014 As per the ClinicalTrials.gov record, the planned end date changed from 1 Jul 2015 to 1 May 2015.